To mark Sarcoidosis Awareness Month, celebrated each April, the Foundation for Sarcoidosis Research (FSR) has launched a global campaign that was sparked by a kaleidoscope. This year’s awareness initiative — dubbed “See Sarcoidosis” — is designed to spotlight the many presentations of sarcoidosis, which affects each patient differently,…
News
While sarcoidosis can lead to hospital admission, in-hospital deaths among people with sarcoidosis are most often caused by other conditions rather than the disease itself, according to a real-world national study in Spain. Common causes of death included infections, cardiovascular disease, cancer, and blood clots known as venous thromboembolism…
People with pulmonary sarcoidosis who are older at diagnosis or have more severe lung damage may face a higher risk of death. That’s according to a large study from Spain, in which researchers found that being older than 50 and having a Composite Physiological Index (CPI) score above 35…
People with autoimmune diseases — especially Sjögren’s disease, which affects the glands that produce tears and saliva — may have a significantly higher risk of developing sarcoidosis, according to a study in Japan. The strongest association was seen with Sjögren’s disease, while other autoimmune conditions were also significantly linked…
Atyr Pharma will meet with the U.S. Food and Drug Administration (FDA) next month to review results from the Phase 3 EFZO-FIT clinical trial and discuss the path forward for efzofitimod as a treatment for pulmonary sarcoidosis. The meeting follows a company announcement last year that the trial…
A bipartisan group of U.S. lawmakers is joining forces to form a new team — the Congressional Sarcoidosis Caucus — to help lead a nationwide fight against sarcoidosis, a rare disease that can affect any of the body’s organs. The newly formed caucus will work to raise awareness about…
The Sarcoidosis Research Institute (SRI) will host a free virtual conference in April aimed at empowering people affected by sarcoidosis. The conference, called Empowering the Patient Journey: Living Well with Sarcoidosis, will take place from 1 to 5 p.m. EST April 25. It will feature expert-led presentations and…
The global burden of pulmonary sarcoidosis and other interstitial lung diseases (ILDs) increased significantly between 1990 and 2023, with rises in new and total cases, deaths, and loss of healthy years, a study showed. The data also showed that the burden varies by region and is highest among adults…
Receiving a high dose of Priovant Therapeutics’ oral treatment candidate brepocitinib in a clinical trial led to substantial reductions in symptom severity for all participants with cutaneous sarcoidosis, in which the disease affects the skin, new data show. Further, no serious side effects were reported in the…
A new artificial intelligence (AI) model predicted sudden cardiac death (SCD) risk more accurately than current clinical guidelines in people with cardiac sarcoidosis, according to a U.S. study. The AI model, called Multimodal Artificial Intelligence for Ventricular Arrhythmia Risk Stratification in Cardiac Sarcoidosis (MAARS-CS), estimates risk using heart MRI…
Recent Posts
- Malaria drug may help treat eye inflammation in ocular sarcoidosis
- Diabetes drug could be repurposed to treat skin sarcoidosis: Study
- Complement proteins show promise as neurosarcoidosis markers
- Genetic variant linked to worsening lung disease in sarcoidosis: Study
- Atyr plans new global clinical trial of efzofitimod in pulmonary sarcoidosis
- Corticosteroids rapidly improve kidney function in renal sarcoidosis: Study
- When pain prevents progress, pursue purpose with passion
- Standard heart ultrasound may aid cardiac sarcoidosis screening
- Sarcoidosis eye risks vary by racial group, study finds
- Study highlights challenges in diagnosing silica-linked diseases